KGX105 for Advanced Solid Tumors That Have Not Improved With Standard Treatment
Part of Cancer clinical trials.
This study tests a new drug called KGX105 as a single treatment for advanced solid tumors. It focuses on cancers that show a marker called EGFR (a protein on some cancer cells), and aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic solid tumor cancer (like lung, head and neck, nasopharyngeal, pancreatic, or stomach cancer) that has progressed or not responded to standard treatments, or where standard therapy is not suitable.
- If your cancer has spread to the brain, it must be stable, small, and not require steroids or seizure medication.
- You must be in good physical condition (able to care for yourself) and have a life expectancy of at least 3 months.
- Your blood counts, liver, and kidney function must be within certain limits.
- If you've had prior cancer treatment, side effects must have mostly resolved (except for hair loss or stable nerve issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.